ZUG, Switzerland, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the Consortium of Independent Immunology Clinics (CIIC) Fall 2023 Conference, to be held from October 13-14, 2023, at the Gaylord Texan Resort in Dallas, TX.
Presentation details:
- Title: Efficacy and safety of bradykinin B2 receptor antagonism with deucrictibant immediate-release capsule for treatment of hereditary angioedema attacks: results of RAPIDe-1 phase ...